Cordis Corporation, a worldwide leader in the development of interventional
vascular technology, today announced it has completed the acquisition of
Flexible Stenting Solutions, Inc., a leading developer of innovative flexible
peripheral arterial, venous and biliary stents.
Currently, Cordis markets the S.M.A.R.T.^® Vascular Stent worldwide. The
addition of Flexible Stenting Solutions' FlexStent^® Self Expanding Stent
System provides Cordis with the opportunity to evolve the S.M.A.R.T.^® Stent
platform to address unmet needs in the treatment of peripheral artery disease
(PAD). It also extends the company's potential to expand therapeutic
applications into below-the-knee and venous interventions. An estimated 27
million people in Europe and North America alone suffer from PAD.
“Cordis continues to identify opportunities to enhance its expanding portfolio
of less invasive treatment options to address the needs of patients suffering
from vascular disease worldwide,” said Shlomi Nachman, Company Group Chairman,
Cordis Corporation. “This acquisition will enable Cordis to provide clinicians
more options to meet their evolving therapeutic needs and to strengthen our
leadership position in the treatment of vascular disease.”
This acquisition marks another milestone in the company's strategy to
strengthen its position in the endovascular market. Recently Cordis received
superficial femoral artery (SFA) and proximal popliteal artery (PPA)
indications for the S.M.A.R.T.^® Stent, the only stent approved in the U.S.
for iliac, SFA and PPA vascular indications. In addition, Cordis offers
market-leading endovascular technology platforms including percutaneous
transluminal angioplasty balloons and chronic total occlusion crossing
devices.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in